Edition:
United States

AMAG Pharmaceuticals Inc (AMAG.OQ)

AMAG.OQ on NASDAQ Stock Exchange Global Select Market

34.00USD
9 Dec 2016
Change (% chg)

$0.15 (+0.44%)
Prev Close
$33.85
Open
$34.20
Day's High
$34.75
Day's Low
$33.60
Volume
149,670
Avg. Vol
239,030
52-wk High
$36.20
52-wk Low
$17.94

Summary

Name Age Since Current Position

Gino Santini

59 2014 Chairman of the Board

Frank Thomas

46 2015 President, Chief Operating Officer

William Heiden

55 2015 Chief Executive Officer, Director

Edward Myles

43 2016 Chief Financial Officer, Senior Vice President - Finance, Treasurer

Nicholas Grund

2016 Executive Vice President, Chief Commercial Officer

Nathan McBride

Senior Vice President - Innovation Architects and Chief Information Officer

Joseph Vittiglio

43 2015 Senior Vice President, General Counsel, Secretary

Todd Van Horn

General Manager - CBR and Senior Vice President - Consumer Marketing & Sales at AMAG

Tony Casciano

2016 Senior Vice President of Sales and Marketing - Hematology and Oncology business

Elizabeth Bolgiano

Senior Vice President of Human Resources

Robert Brenner

45 2008 Senior Vice President - Medical Affairs

Melissa Klug

2014 Senior Vice President - Business Development & Strategy

Julie Krop

2015 Chief Medical Officer and Senior Vice President - Clinical Development and Regulatory Affairs

Scott McMillan

2013 Senior Vice President - Quality and Technical Operations

Paul Williams

Senior Vice President - Sales and Marketing, Lumara Health and Cord Blood Registry

Kathryn Payne

2015 Vice President - External Affairs.

Mark Stanton

2016 Vice President - Market Access and Corporate Accounts

John Fallon

68 2014 Director

Barbara Deptula

60 2013 Independent Director

Robert Perez

51 2009 Independent Director

Cooper Russell

55 2009 Independent Director

Davey Scoon

68 2006 Independent Director

James Sulat

66 2014 Independent Director

Linda Lennox

2015 Vice President of Investor Relations, & Corporate Communications

Biographies

Name Description

Gino Santini

Mr. Gino Santini is Chairman of the Board of AMAG Pharmaceuticals, Inc. Santini retired from distinguished career with Eli Lilly and Company that spanned nearly three decades. During his tenure at Lilly, Mr. Santini held various leadership positions of increasing responsibility, including manager of various international regions, senior vice president of corporate strategy and policy, president of the women’s health franchise and president of U.S. operations. Mr. Santini capped his career at Lilly as a member of the company’s executive committee and as the Senior Vice President of Corporate Strategy and Business Development. Mr. Santini currently serves on the boards of directors of Intercept Pharmaceuticals, Inc., Intarcia Therapeutics, Inc., Sorin S.p.A., Collegium Pharmaceuticals, Inc., Allena Pharmaceuticals, Inc., and Artax Biopharma Inc. In addition, Mr. Santini serves on the board of directors for Vitae Pharmaceuticals, Inc. where he is also the chair of the governance and nominating committee, as well as Horizon Pharma, Plc. where he is also chair of the transactions committee. Mr. Santini, fluent in four languages, holds an undergraduate degree in mechanical engineering from the University of Bologna and a MBA from the University of Rochester.

Frank Thomas

Mr. Frank E. Thomas is President, Chief Operating Officer of the Company. He was Chief Operating Officer, Executive Vice President of AMAG Pharmaceuticals Inc. He joined in August 2011 as Executive Vice President, Chief Financial Officer and Treasurer and currently serves as Executive Vice President and Chief Operating Officer. From November 2011 to May 2012, he also served as Interim President and Chief Executive Officer. Prior to joining, he served as Senior Vice President, Chief Operating Officer and Chief Financial Officer for Molecular Biometrics, Inc., or Molecular Biometrics, a commercial stage medical diagnostics company, from October 2008 to July 2011. Prior to Molecular Biometrics, Mr. Thomas spent four years at Critical Therapeutics, Inc., or Critical Therapeutics, a public biopharmaceutical company, from 2004 to 2008, where he was promoted to President in June 2006 and Chief Executive Officer in December 2006 from the position of Senior Vice President and Chief Financial Officer. He also served on the Board of Directors of Critical Therapeutics from 2006 to 2008. Prior to 2004, Mr. Thomas was the Chief Financial Officer and Vice President of Finance and Investor Relations at Esperion Therapeutics, Inc. Since 2007, he has been a member of the Board of Directors of the Massachusetts Biotechnology Council. Mr. Thomas holds a B.B.A. in Business Administration from the University of Michigan, Ann Arbor.

William Heiden

Mr. William K. Heiden is Chief Executive Officer, Director of the Company. He is an experienced pharmaceutical and biotechnology executive who has been chief Executive officer of AMAG since May 2012 and served as President from May 2012 through April 2015. Mr. Heiden joined AMAG from GTC Biotherapeutics, Inc., now rEVO Biologics, Inc., where he had served as president and chief executive officer from 2010 to 2012 and chairman of the board of directors from 2007 to 2013. Prior to joining GTC Biotherapeutics, Mr. Heiden was the president and chief executive officer and a member of the board of directors of Elixir Pharmaceuticals, Inc., from 2004 to 2008. Prior to joining Elixir Pharmaceuticals, Mr. Heiden served as president and chief operating officer of Praecis Pharmaceuticals Incorporated (which was acquired by GlaxoSmithKline plc), from 2002 to 2004. From 1987 to 2002, Mr. Heiden held various positions of increasing responsibility at Schering-Plough Corporation (now Merck & Co.), including managing a number of businesses in the United States, Europe and Canada. Mr. Heiden currently serves on the board of directors for Atara Biotherapeutics, Inc. Mr. Heiden holds a BA degree from the University of Florida, a MIM degree from the University of Louvain, and a MBA from Cornell University’s Johnson Graduate School of Management.

Edward Myles

Mr. Edward Myles CPA, is Chief Financial Officer, Senior Vice President - Finance, Treasurer of the Company. Prior to joining the Company, Mr. Myles served in various positions at Ocata Therapeutics, Inc. (“Ocata”), from June 2013 to April 2016, most recently as Chief Financial Officer and Chief Operating Officer. Prior to Ocata, Mr. Myles served as Chief Financial Officer and Vice President of Operations at PrimeraDx, Inc. from November 2008 to June 2013. He also served as Senior Vice President of Finance and Chief Financial Officer at Pressure Biosciences, Inc. from April 2006 to November 2008 and Controller at EMD Pharmaceuticals, Inc. (a wholly-owned subsidiary of Merck KGaA) from May 2003 to April 2006. Earlier in his career, Mr. Myles was an Associate in the healthcare investment banking group at SG Cowen Securities Corporation and served as Corporate Controller for Boston Biomedica, Inc. Mr. Myles began his career at PriceWaterhouseCoopers LLP where he served a variety of clients in the life sciences and technology industries. Mr. Myles holds a bachelor’s of science degree in business administration from University of Hartford and an M.B.A. from the John M. Olin School of Business, Washington University.

Nicholas Grund

Mr. Nicholas (Nik) Grund is Executive Vice President, Chief Commercial Officer of the Company. He joined AMAG in January 2016 and brings more than 20 years of commercial leadership experience in the biopharmaceutical industry, including several global senior-level executive roles in sales and marketing. He joins AMAG from Genzyme Corporation, a Sanofi Company, where he spent the past 13 years in business leadership roles, most recently as the leader of the company’s rare disease and multiple sclerosis franchises in Asia Pacific and Canada. Mr. Grund joined Genzyme from Bayer Diagnostics where he progressed through a number of senior finance roles in the Critical Care Business Unit from 1995 to 2002. Mr. Grund holds a bachelor’s of science degree in business administration from the University of Massachusetts and a master’s of business administration from Northeastern University.

Nathan McBride

Mr. Nathan McBride is Senior Vice President - Innovation Architects and Chief Information Officer of the company. He has more than 18 years of experience managing both small and large information technology teams primarily in the biopharmaceutical industry. He joined AMAG in January 2008 and is responsible for all information technology operations including business management software integrations for key corporate initiatives, security, application development, database design and enterprise wide implementations. He is also responsible for the facilities management of all properties leased by AMAG. Prior to joining AMAG, he served as senior director of business and scientific applications at Cubist Pharmaceuticals from 2005 to 2008. Prior to his time at Cubist, Mr. McBride served as senior director of information technology at Transkaryotic Therapies, Inc., now Shire Pharmaceuticals, from 1999 to 2005 and the director of technology at Cushing Academy from 1997 to 1999. He began his career in information technology in 1996 as an assistant manager and teacher at Rye Country Day School. Mr. McBride holds a bachelor of arts in classics degree from Connecticut College.

Joseph Vittiglio

Mr. Joseph Vittiglio is Senior Vice President, General Counsel, Secretary of AMAG Pharmaceuticals, Inc. He has more than 18 years of legal and operations experience counseling biopharmaceutical and specialty pharmaceutical companies in product development, commercialization and launch, corporate finance and partnering transactions, securities law, merger and acquisitions, corporate governance and litigation. He most recently served as vice president of legal affairs and a member of the management committee at Flexion Therapeutics, Inc. Prior to that, Mr. Vittiglio was the general counsel of AVEO Pharmaceuticals for eight years. Mr. Vittiglio also gained relevant commercial experience serving as director of legal affairs at Oscient Pharmaceuticals Corporation. He began his legal career as an associate attorney at Gaffin & Krattenmaker, P.C. before joining Mintz, Levin, Cohn, Ferris, Glovsky and Popeo PC as a senior attorney in 1998 specializing in complex collaborations, securities law, mergers and acquisitions, and venture capital. Mr. Vittiglio holds a bachelor’s degree in international relations from Tufts University and a juris doctor from Northeastern University School of Law.

Todd Van Horn

Mr. Todd H. Van Horn is General Manager - CBR and Senior Vice President - Consumer Marketing & Sales at AMAG of the company. He is an experienced healthcare executive who joined AMAG Pharmaceuticals as part of the company’s recent acquisition of Cord Blood Registry (CBR) and serves as General Manager of CBR and Senior Vice President of Consumer Marketing & Sales at AMAG. Prior to joining AMAG, Mr. Van Horn served as vice president at CBR overseeing its business intelligence team and all business development activities, strategic partnerships, mergers and acquisitions, and collaborations. Prior to joining CBR, he served as a principal at Linden Capital Partners, a healthcare and life sciences-focused private equity firm where he served as a board director or observer on several portfolio companies. Prior to Linden, Mr. Van Horn was a principal and founding member of Healthcare Investment Partners, a growth equity healthcare fund, and began his career in the healthcare investment banking group at Credit Suisse First Boston. Mr. Van Horn holds a bachelor’s of science degree in molecular, cell and developmental biology from the University of California and a master’s of business administration from the Kellogg School of Management.

Tony Casciano

Mr. Tony Casciano has been appointed as Senior Vice President of Sales and Marketing - Hematology and Oncology business of the Company. Mr. Casciano brings to AMAG more than 15 years of sales and marketing experience and began his career at Sanofi US in 2000. He has advanced through commercial positions of increasing responsibility across a broad range of therapeutic areas, and most recently served as the head of marketing for Sanofi where he led the General Medicine division. Mr. Casciano holds a Bachelor of Science degree in business administration from Bridgewater State College.

Elizabeth Bolgiano

Ms. Elizabeth Bolgiano is Senior Vice President of Human Resources of the company. She is an experienced human resources professional who joined AMAG in January 2014 as senior vice president of human resources. Ms. Bolgiano joined AMAG Pharmaceuticals from Thermo Fisher Scientific where she served as senior vice president of human resources and a member of the executive team since 2010. Prior to joining Thermo Fisher Scientific, Ms. Bolgiano served as group human resources director of Smith & Nephew Company from 2007 to 2010 and senior vice president of human resources from 2004 to 2006. From 1989 to 2004, Ms. Bolgiano progressed through various positions of increasing responsibility at Bristol-Myers Squibb Company. Ms. Bolgiano has significant experience across the spectrum of human resources including organizational development, strategy, talent acquisition, employee relations, compensation, and leadership development and training. She holds a Master’s degree in business administration, as well as a Bachelor’s degree, from Cornell University.

Robert Brenner

Dr. Robert M. Brenner, M.D. is Senior Vice President - Medical Affairs of the company. He joined AMAG Pharmaceuticals in October 2013 and brings more than 20 years of healthcare experience in the global biopharmaceutical industry. He joins AMAG from Teva Pharmaceuticals where he most recently served as vice president of global medical affairs for their expanding branded portfolio. Dr. Kaper has significant experience across all functions in medical affairs in the therapeutic areas of neurology, oncology, immunology, women’s health and pain management. Through his medical affairs leadership roles at Cephalon and Organon, he successfully formulated strategic clinical development plans, implemented life cycle management programs and supported the commercialization of new products. Dr. Kaper received his medical degree from the Free University in Amsterdam with postgraduate training in neurosurgery at the Slotervaart Hospital and orthopedic surgery at the Academic Hospital of the Free University in Amsterdam.

Melissa Klug

Ms. Melissa Bradford Klug is Senior Vice President - Business Development & Strategy of the company. She joined AMAG in June 2014 as senior vice president of business development and strategy. Prior to joining AMAG, Ms. Klug served as vice president of corporate development at Mallinckrodt Pharmaceuticals since 2004 and during that time, completed a number of significant transactions, including two corporate development transactions within six months of Mallinckrodt’s spin out of Coviden. Prior to joining Mallinckrodt, Ms. Klug held leadership roles in business development at Baxter International and Eli Lilly and Company. Ms. Klug has more than 15 years of hands-on strategic planning, licensing, and business development experience in the life sciences industry. She has executed multiple business development transactions and established key financial metrics to support investments or acquisitions of new technologies, assets and companies, including the acquisition of CNS Therapeutics and two Phase III assets that formed the foundation for a pain franchise and generated more than $250 million in revenue annually. Ms. Klug has been a member of the Board of Directors of the Massachusetts Biotechnology Council since March 2015. Ms. Klug holds a Bachelor of Science degree in Chemistry from Maryville University and a Master of Business Administration from DePaul University.

Julie Krop

Dr. Julie Krop, M.D. is Chief Medical Officer and Senior Vice President - Clinical Development and Regulatory Affairs of the company. She joined AMAG in June 2015 and brings more than 15 years of experience in drug development, working with clinical teams in the strategic design and execution of development plans, and leading the preparation and participation in pre-approval FDA advisory panel presentations and discussions. In addition, she has worked with the FDA and European Medicines Agency (EMEA) to obtain drug approvals in the U.S. and Europe. She joins AMAG from Vertex Pharmaceuticals, where she most recently served as vice president, clinical development. Dr. Krop began her career in clinical research in 1991 at Pfizer Pharmaceuticals and has since held various leadership positions at Stryker Regenerative Medicine, Peptimmune, and Millennium Pharmaceuticals. Dr. Krop received her bachelor’s degree from Brown University and her medical degree from the Brown University School of Medicine. She completed her residency in the Department of Medicine at Georgetown University Hospital and a fellowship in the Department of Endocrinology at the Johns Hopkins University School of Medicine.

Scott McMillan

Dr. Scott T. McMillan is Senior Vice President - Quality and Technical Operations of the company. Since January 2013, he was promoted to senior vice president, quality and technical operations. Dr. McMillan joined AMAG from AVANT Immunotherapeutics, Inc. (now Celldex Therapeutics, Inc.), a public biopharmaceutical company, where he held various roles of increasing responsibility from 2005 to 2008, including senior director, manufacturing operations/process development. Prior to his time with AVANT, he was director, purification operations at Johnson Matthey Pharmaceutical Materials, Inc., an international specialty chemicals company. Dr. McMillan holds a B.S. in Chemical Engineering from the University of Delaware and a Ph.D. in Chemical Engineering from the Georgia Institute of Technology. Since 2010, he has served as a member of the Industrial Advisory Board of the Department of Chemical Engineering at Northeastern University.

Paul Williams

Mr. Paul Williams is Senior Vice President - Sales and Marketing, Lumara Health and Cord Blood Registry of the company. He serves as senior vice president of sales and marketing for the Lumara Health and Cord Blood Registry (CBR) divisions of AMAG. Mr. Williams joined AMAG with more than 25 years of sales and marketing experience as part of the company’s acquisition of Lumara Health in November 2014. As vice president of the women’s healthcare division and commercial operations of Lumara Health, he led the build-out and re-launch of the company’s product portfolio in anti-infectives and hormone replacement therapy. Prior to joining Lumara Health, Mr. Williams served as senior vice president and general manager of a division of Actavis, Inc. Prior to Actavis, Mr. Williams held positions of increasing sales and marketing responsibility at Medimmune LLC, a member of the AstraZeneca Group, and Centocor, Inc., a Johnson & Johnson Company. Mr. Williams holds a bachelor’s of science degree in finance from Virginia Polytechnic Institute and State University.

Kathryn Payne

Ms. Kathryn Carr Payne is Vice President - External Affairs. of the company. She is directs AMAG’s communications and public affairs activities, which include leading the company’s public relations and policy and advocacy initiatives at the state and federal level. Ms. Payne has nearly 15 years of experience in public relations and issue advocacy, specializing in using communications and stakeholder engagement to advance business and policy objectives. She joined AMAG in May 2014 from APCO Worldwide, a global public affairs and strategic communications firm based in Washington D.C., where she spent 10 years in various positions of increasing responsibility, including most recently as vice president and director. During her time at APCO, Ms. Payne led corporate communications, policymaker outreach and brand-building programs designed to position pharmaceutical and biotechnology companies, their products, issues and leadership to external audiences, including media, investors, customers and patients. Prior to joining APCO, Ms. Payne served as a communications associate at the World Bank in Washington, D.C., and as a healthcare research associate at Forrester Research, a publicly traded research and advisory firm based in Cambridge, Mass. Ms. Payne graduated Phi Beta Kappa and with high honors from The Johns Hopkins University with a bachelor’s degree in writing and business management and a master’s degree in communications.

Mark Stanton

Mr. Mark Stanton is Vice President - Market Access and Corporate Accounts of the Company. He brings to AMAG more than 30 years of experience, most recently serving at AstraZeneca as the head of market access optimization since 2015 and the head of the U.S. diabetes market access function since 2013. From 2007 to 2013, Mr. Stanton served as the vice president for market access and reimbursement for Medimmune, Inc., an AstraZeneca Biologics Division. Prior to that, Mr. Stanton served in a variety of corporate accounts and sales roles at a number of pharmaceutical companies. Mr. Stanton holds a Bachelor of Science degree in business administration from Castleton State College, Vermont.

John Fallon

Dr. John A. Fallon, M.D., is an Director of AMAG Pharmaceuticals, Inc., Since September 2014. Dr. Fallon most recently served as senior vice president and chief physician executive at Blue Cross & Blue Shield of Massachusetts (BCBS) from 2004 to 2015. Prior to his role at BCBSMA, Dr. Fallon served as chief executive officer for clinical affairs at the State University of New York Downstate Medical Center, including University Hospital of Brooklyn and the clinical faculty practice plan. His professional experience also includes the Partners Healthcare System, where he was chairman of the physician network. Dr. Fallon was the founder and CEO of North Shore Health System, a large physician-hospital organization in Massachusetts. He serves as lead director for the board of directors of Insulet Corporation, and serves on the board of directors for Exact Sciences. He also serves on several not-for-profit boards, including NEHI (Network for Excellence in Health Innovation) (Chair), National Committee for Quality Assurance (NCQA) Medical Standards (Chair), New England Comparative Effectiveness Public Advisory Council (CEPAC) and Temple University School of Medicine Board of Advisors. Dr. Fallon practiced internal medicine for more than 20 years, fulfilled his residency at Boston City Hospital, is Board Certified in Internal Medicine and is a fellow of the American College of Physicians. He received a bachelor’s degree from the College of the Holy Cross, a master’s degree in business administration from the University of South Florida and a medical degree from Tufts University School of Medicine.

Barbara Deptula

Ms. Barbara H. Deptula is an Independent Director of AMAG Pharmaceuticals, Inc., She has been a director since September 2013. Ms. Deptula brings to the AMAG board broad-based corporate development expertise obtained through her distinguished 30-year career in a variety of biotechnology and multi-national pharmaceutical organizations. Ms. Deptula began working at Shire Pharmaceuticals in 2004, and retired in 2012 from her position as executive vice president and chief corporate development officer, and a member of Shire’s leadership team. During her tenure at Shire, the company deployed nearly five billion dollars acquiring a range of companies and products, and established an independent venture capital arm. Prior to joining Shire, Ms. Deptula was president of the biotechnology division of Sicor Inc. and senior vice president for commercial and product development at Coley Pharmaceutical Group. She also held senior management positions focused on marketing, product development, licensing and business development at US Bioscience, Schering Plough, American Cyanamid, and Genetics Institute. Ms. Deptula received a BS degree from the University of Connecticut’s School of Pharmacy and a MBA from the University of Chicago.

Robert Perez

Mr. Robert J. Perez is Independent Director of AMAG Pharmaceuticals Inc. He is formerly served as president and chief operating officer of Cubist Pharmaceuticals, Inc. Mr. Perez joined Cubist in 2003, as senior vice president, sales and marketing and led the launch of Cubicin® (daptomycin for injection). Prior to joining Cubist, he served as vice president of Biogen, Inc.’s CNS Business Unit from 2001 to 2003, where he was responsible for commercial leadership of an $800 million neurology business unit and from 1995 to 2001, held positions of increasing responsibility within the commercial organization. From 1987 to 1995, Mr. Perez held various sales and marketing positions at Zeneca Pharmaceuticals. Mr. Perez is currently a member of the board of trustees of the Dana-Farber Cancer Institute, Inc., and the board of advisors of the Citizen School of Massachusetts. Mr. Perez serves on numerous boards including Zafgen, Inc., Flex Pharma, Inc., Cidara Pharmaceuticals, College Bound Dorchester, and the Biomedical Science Careers Program. Mr. Perez received a BS from California State University, Los Angeles and a MBA from The Anderson School at UCLA.

Cooper Russell

Dr. Lesley Russell Cooper, MB.Ch.B., MRCP, is an Independent Director of AMAG Pharmaceuticals Inc. She has been a director since December 2009. Dr. Russell has served as the chief operating officer of TetraLogics Pharmaceuticals since August 2013. Prior to TetraLogics, she was the senior vice president and global head of research and development for Teva Pharmaceuticals, Inc., a role which she was appointed to after Teva acquired Cephalon. While at Cephalon from 2006 to 2011, Dr. Russell served as executive vice president and chief medical officer. Prior to joining Cephalon in 2000, Dr. Russell worked for several pharmaceutical organizations, including US Biosciences, Eli Lilly and Amgen. Before joining the pharmaceutical industry, she was trained in hematology/oncology at Royal Infirmary of Edinburgh and at Royal Hospital for Sick Children in Edinburgh, UK and was a Research Fellow at University of Edinburgh Faculty of Medicine. Dr. Russell currently serves on the board of directors of Endoycte, Inc. Dr. Russell received a MB.Ch.B. degree from the University of Edinburgh, Scotland, Faculty of Medicine. She is a member of the Royal College of Physicians, UK, and is registered with the General Medical Council, UK.

Davey Scoon

Mr. Davey S. Scoon, CPA, is Independent Director of AMAG Pharmaceuticals Inc. He has more than 30 years experience in finance and administration in executive positions. From 2003 to 2005, Mr. Scoon was chief administrative and financial officer of Tom’s of Maine, a company that manufactures natural care products. From 2001 to 2003, Mr. Scoon served as chief financial and administrative officer for Sun Life Financial U.S. and from 1999 to 2001, Mr. Scoon served as vice president and chief financial officer for Sun Life Financial U.S. From 1985 to 1999, Mr. Scoon was employed by Liberty Funds Group of Boston (formerly Colonial Management) in various capacities including chief financial officer and chief operating officer. Mr. Scoon served as chairman of the board of directors of Tufts Health Plan as a director from 1981 to 2015. He currently serves as chairman of the board of trustees of Allianz Funds and is a member of the board of directors of Biodel Inc. He has been an Adjunct Professor at the University of Wisconsin-Madison School of Business since 2010. Mr. Scoon holds a BBA from the University of Wisconsin and a MBA from Harvard Business School and is a CPA.

James Sulat

Mr. James R. Sulat is Independent Director of the Company. He served as the chief executive officer and chief financial officer of Maxygen, Inc. from 2009 to 2013, and as a member of its board of directors from 2003 to 2013. From 2005 to 2009, Mr. Sulat served as president and chief executive officer and then as chief financial officer of Memory Pharmaceuticals Corp. from 2005 to 2008, as well as a member of its board of directors from 2005 to 2009. Prior to these roles, Mr. Sulat was the chief financial officer in several different large and mid-sized public companies. Mr. Sulat serves as chairman of the board of directors for Momenta Pharmaceuticals, Inc., and on the board of directors of Arch Therapeutics, Inc., Diadexus, Inc., and Valneva SE. Mr. Sulat received a BS in Administrative Sciences from Yale University, and a MBA and a MS in Health Services Administration from Stanford University.

Linda Lennox

Ms. Linda Lennox is Vice President of Investor Relations, & Corporate Communications of AMAG Pharmaceuticals, Inc. Ms. Lennox has 25 years of leadership experience with companies in the healthcare and energy sectors. Prior to joining AMAG, Ms. Lennox served as senior director, investor relations & corporate communications at Lantheus Medical Imaging, Inc., a privately held global diagnostic imaging company. Prior to that, Ms. Lennox served as vice president, investor & media relations at Critical Therapeutics, a publicly traded biotechnology/specialty pharmaceutical company. Prior to joining Critical Therapeutics, Ms. Lennox spent 15 years in positions of increasing responsibility at two separate publicly traded energy companies. Ms. Lennox started her career at Putnam Investments and Smith Barney, where she obtained her series 6, 7 and 63 licenses. She received a bachelor's degree in economics from the University of Vermont.